Subsequent Events	9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events On October 7, 2025, ITH entered into a Series B Preferred Stock Purchase Agreement with Beacon Biosignals, Inc. (“Beacon”) to purchase 1,448,303 shares of Beacon Series B preferred stock for $17.5 million. Beacon is an AI-driven neurotechnology company developing treatments for neurological, psychiatric and sleep disorders. On November 3, 2025, our board of directors authorized a new share repurchase program under which we may repurchase up to $125.0 million of our outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements and will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions, and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not obligate us to acquire any amount of common stock.

Subsequent Events

9 Months Ended

Sep. 30, 2025

16. Subsequent Events

On October 7, 2025, ITH entered into a Series B Preferred Stock Purchase Agreement with Beacon Biosignals, Inc. (“Beacon”) to purchase 1,448,303 shares of Beacon Series B preferred stock for $17.5 million. Beacon is an AI-driven neurotechnology company developing treatments for neurological, psychiatric and sleep disorders.

On November 3, 2025, our board of directors authorized a new share repurchase program under which we may repurchase up to $125.0 million of our outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements and will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions, and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not obligate us to acquire any amount of common stock.